Cryo-Cell receives NYSE American compliance plan acceptance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Wall Street ends higher as tech rebounds before Nvidia results
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
- Dick's Sporting Goods (DKS) Misses Q2 EPS by 25c, Offers Guidance
Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American
May 8, 2026 4:00 PM EDTOLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the NYSE American") has accepted the Companys previously submitted plan to regain compliance with continued listing standards.
As previously disclosed on March 12, 2026, the Company was notified that it was not in compliance with Section 1003 (a) of the NYSE American Company Guide because the Company reported (i) a stockholders deficit as of November 30, 2025, and (ii) net... More
